Latest filing published 27 Nov 2020 for Eucrates Biomedical Acquisition Corp..
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Parag Saxena: trading record in brief
This profile gathers the share dealings of Parag Saxena across 2 companies, led by Reviva Pharmaceuticals Holdings, Inc. and Eucrates Biomedical Acquisition Corp. The record holds 3 filings, for trades running from 23 August 2018 to 24 November 2020.
Every open-market trade on record is a purchase: 2 purchases worth €3.0M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
The latest filing, published on 27 November 2020, reports a transaction in Eucrates Biomedical Acquisition Corp. The last insider purchase was made public on 4 September 2018, 2,987 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Parag Saxena
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 255,094 sharesOrdinary SharesSEC:0001104659-20-130017:0
- 33,000 shares@ US$10.00Ordinary SharesSEC:0001144204-18-047839:0Canonical exit: 28 Nov 2018 (T+90)
- 310,000 shares@ US$10.00Ordinary SharesSEC:0001144204-18-046298:0Canonical exit: 21 Nov 2018 (T+90)
3 of 3 declarations